Prinomastat

Prinomastat (AG3340) is a broad spectrum, potent, orally active metalloproteinase (MMP) inhibitor with IC50s of 79, 6.3 and 5.0 nM for MMP-1, MMP-3 and MMP-9, respectively. Prinomastat inhibits MMP-2, MMP-3, MMP-13 and MMP-9 with Kis of 0.05 nM, 0.3 nM, 0.03 nM and 0.26 nM, respectively. Prinomastat crosses blood-brain barrier. Antitumor avtivity[1][2][3][4].

Product Specifications

CAS Number

[192329-42-3]

Product Name Alternative

AG3340; KB-R9896

UNSPSC

12352005

Hazard Statement

H360

Target

Apoptosis; MMP

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Prinomastat.html

Purity

99.27

Solubility

1 M HCl : 25 mg/mL (ultrasonic) |DMSO : < 1 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 2.5 mg/mL (ultrasonic; adjust pH to 3 with HCl)

Smiles

O=C([C@@H]1N(S(=O)(C2=CC=C(OC3=CC=NC=C3)C=C2)=O)CCSC1(C)C)NO

Molecular Formula

C18H21N3O5S2

Molecular Weight

423.51

Precautions

H360

References & Citations

[1]Sørensen MD, et al. Cyclic phosphinamides and phosphonamides, novel series of potent matrix metalloproteinase inhibitors with antitumour activity. Bioorg Med Chem. 2003 Dec 1;11 (24) :5461-84.|[2]Blavier L, et al. Stromelysin-1 (MMP-3) is a target and a regulator of Wnt1-induced epithelial-mesenchymal transition (EMT) . Cancer Biol Ther. 2010 Jul 15;10 (2) :198-208.|[3]Shalinsky DR, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci. 1999 Jun 30;878:236-70.|[4]Ozerdem U, et al. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy. Curr Eye Res. 2000 Jun;20 (6) :447-53.